Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

JDRF, BD To Develop Glucose Monitoring Devices For Type 1 Diabetes - Quick Facts

RELATED NEWS
Trade BDX now with 

JDRF and Becton, Dickinson and Co. or BD (BDX: Quote) extended their existing collaboration focused on Type 1 diabetes or T1D to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and reliable continuous glucose information. JDRF and Helmsley Charitable Trust or HCT joined forces to support novel technologies that would be essential for developing fully automated artificial pancreas systems with advanced monitoring capabilities.

The research expansion is part of the JDRF-HCT Sensor Initiative designed to accelerate the development of advanced sensors that improve the detection of changing glucose levels.

"While we continue to search for the elusive cure, we must give people with T1D better tools to ease the burden of managing their disease, and this project is a step forward toward that goal," said David Panzirer, Trustee, The Helmsley Charitable Trust.

Click here to receive FREE breaking news email alerts for Becton, Dickinson and Company and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and regularly increasing its annual earnings forecast, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's top-line and bottom-line results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.